Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from...
Read More Details
Finally We wish PressBee provided you with enough information of ( TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years )
Also on site :
- Hamas executes Palestinians for looting as desperation grows under Israeli blockade
- South Sacramento standoff ends with suspect surrendering to SWAT officers
- Giveaway: Enter to win tickets for ‘Hello, Dolly!’